Scientists at The Scripps Research Institute and The Skaggs Institute for Chemical Biology have developed a unique assembly strategy to produce an anti-cancer targeting antibody, an approach that combines the merits of small molecule drug design with immunotherapy. Among the potential therapeutic advantages is a dramatically increased circulatory half-life of the compound, which could give patients greater exposure to the benefits of any treatment.
